17634483

Source:http://linkedlifedata.com/resource/pubmed/id/17634483

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0201734, umls-concept:C0205054, umls-concept:C0205390, umls-concept:C0280100, umls-concept:C1135135, umls-concept:C1516238, umls-concept:C1848822
pubmed:issue	21
pubmed:dateCreated	2007-7-19
pubmed:abstractText	We investigated dose and pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA 02599, http://linkedlifedata.com/resource/pubmed/grant/CA 03927, http://linkedlifedata.com/resource/pubmed/grant/CA 04326, http://linkedlifedata.com/resource/pubmed/grant/CA 11028, http://linkedlifedata.com/resource/pubmed/grant/CA 31946, http://linkedlifedata.com/resource/pubmed/grant/CA 31983, http://linkedlifedata.com/resource/pubmed/grant/CA 33601, http://linkedlifedata.com/resource/pubmed/grant/CA 35279, http://linkedlifedata.com/resource/pubmed/grant/CA 37135, http://linkedlifedata.com/resource/pubmed/grant/CA 41287, http://linkedlifedata.com/resource/pubmed/grant/CA 47577, http://linkedlifedata.com/resource/pubmed/grant/CA 47642, http://linkedlifedata.com/resource/pubmed/grant/CA 77597, http://linkedlifedata.com/resource/pubmed/grant/CA 77658
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines, http://linkedlifedata.com/resource/pubmed/chemical/erlotinib
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1527-7755
pubmed:author	pubmed-author:EdelmanMartin JMJ, pubmed-author:HohlRaymond JRJ, pubmed-author:HollisDonna RDR, pubmed-author:KindlerHedy LHL, pubmed-author:LewisLionel DLD, pubmed-author:LichtmanStuart MSM, pubmed-author:MarshallJohn LJL, pubmed-author:MillerAntonius AAA, pubmed-author:MurryDaryl JDJ, pubmed-author:OwzarKourosK, pubmed-author:RatainMark JMJ, pubmed-author:Villalona-CaleroMiguel AMA
pubmed:issnType	Electronic
pubmed:day	20
pubmed:volume	25
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	3055-60
pubmed:dateRevised	2007-12-3
pubmed:meshHeading	pubmed-meshheading:17634483-Administration, Oral, pubmed-meshheading:17634483-Adult, pubmed-meshheading:17634483-Aged, pubmed-meshheading:17634483-Dose-Response Relationship, Drug, pubmed-meshheading:17634483-Drug Administration Schedule, pubmed-meshheading:17634483-Female, pubmed-meshheading:17634483-Follow-Up Studies, pubmed-meshheading:17634483-Humans, pubmed-meshheading:17634483-Kidney Diseases, pubmed-meshheading:17634483-Kidney Function Tests, pubmed-meshheading:17634483-Liver Diseases, pubmed-meshheading:17634483-Liver Function Tests, pubmed-meshheading:17634483-Male, pubmed-meshheading:17634483-Maximum Tolerated Dose, pubmed-meshheading:17634483-Middle Aged, pubmed-meshheading:17634483-Neoplasm Staging, pubmed-meshheading:17634483-Neoplasms, pubmed-meshheading:17634483-Probability, pubmed-meshheading:17634483-Quinazolines, pubmed-meshheading:17634483-Risk Assessment, pubmed-meshheading:17634483-Survival Analysis, pubmed-meshheading:17634483-Treatment Outcome
pubmed:year	2007
pubmed:articleTitle	Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
pubmed:affiliation	Wake Forest University School of Medicine, Winston-Salem, NC 27157-1082, USA. aamiller@wfubmc.edu
pubmed:publicationType	Journal Article, Clinical Trial, Phase I, Research Support, N.I.H., Extramural